{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:18:11Z","timestamp":1772749091519,"version":"3.50.1"},"reference-count":83,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"Asociaci\u00f3n de Reumat\u00f3logos del Hospital de Cruces","award":["04\/2015"],"award-info":[{"award-number":["04\/2015"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2016,5,3]]},"DOI":"10.1586\/17512433.2016.1162094","type":"journal-article","created":{"date-parts":[[2016,3,4]],"date-time":"2016-03-04T15:11:21Z","timestamp":1457104281000},"page":"665-673","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":28,"title":["Febuxostat for the chronic management of hyperuricemia in patients with gout"],"prefix":"10.1586","volume":"9","author":[{"given":"Sandra Pamela","family":"Chinchilla","sequence":"first","affiliation":[{"name":",","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irati","family":"Urionaguena","sequence":"additional","affiliation":[{"name":",","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Perez-Ruiz","sequence":"additional","affiliation":[{"name":",","place":["Spain"]},{"name":"Biocruces Health Research Institute, Baracaldo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,3,25]]},"reference":[{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2010.10.004"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.91"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.109884"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204647"},{"key":"e_1_3_3_9_1","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","author":"Vos T","year":"2015","unstructured":"Vos T, Barber RM, Bell B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Jun 7;pii:S01406736(15)606924.","journal-title":"Lancet"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30520"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23176"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204463"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.024091"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjopharm.2011.07.004"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker361"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201687"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22767"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-014-0175-z"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2010.540874"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.124"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.32"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055269"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21773"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60883-7"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00757949"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/ijnrd.s5563"},{"key":"e_1_3_3_27_1","first-page":"CD006077","article-title":"Allopurinol for chronic gout","volume":"10","author":"Seth R","year":"2014","unstructured":"Seth R, Kydd AS, Buchbinder R, et al. Allopurinol for chronic gout. Cochrane Database Syst Rev. 2014 Oct 14;10:CD006077.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"e_1_3_3_28_1","first-page":"CD010457","article-title":"Uricosuric medications for chronic gout","volume":"14","author":"Kydd AS","year":"2014","unstructured":"Kydd AS, Seth R, Buchbinder R, et al. Uricosuric medications for chronic gout. Cochrane Database Syst Rev. 2014 Nov;14(11):CD010457.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-014-3189-6"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000146"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.2217\/17460816.3.5.421"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M208307200"},{"key":"e_1_3_3_33_1","unstructured":"The vision of Febuxostat. Teijin Pharma Limited. Project stories Vol. 01. Japan. 2013. [cited 2015 Aug 23]. Available from: http:\/\/www.teijin-pharma.com\/project\/story01.html"},{"key":"e_1_3_3_34_1","unstructured":"Adenuric. European Medicines Agency. Human medicines. Authorisation details. United Kingdom. 2015. [cited 2015 Aug 19]. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000777\/human_med_000627.jsp&mid=WC0b01ac058001d124"},{"key":"e_1_3_3_35_1","volume-title":"Summary of product characteristics","author":"Adenuric","unstructured":"Adenuric. Summary of product characteristics [Internet]. [cited 2016 Mar 15]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000777\/WC500021812.pdf"},{"key":"e_1_3_3_36_1","unstructured":"Uloric. U. S Food and Drug Administration. Drug approval package. United States. 2009. [cited 2015 Aug 19]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/021856s000toc.cfm"},{"key":"e_1_3_3_37_1","unstructured":"The Pharmaceuticals and Medical Devices Agency [Internet]. [cited 2016 Mar 15]. Available from: https:\/\/ss.pmda.go.jp\/en_all\/search.x?q=febuxostat"},{"key":"e_1_3_3_38_1","volume-title":"Full prescribing information","author":"Uloric","unstructured":"Uloric. Full prescribing information [Internet]. [cited 2016 Mar 15]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021856s006lbl.pdf"},{"issue":"9","key":"e_1_3_3_39_1","first-page":"1549","article-title":"Hyperuricemia and tissue monourate deposits: prospective therapeutic considerations","volume":"19","author":"Perez-Ruiz F","year":"2015","unstructured":"Perez-Ruiz F, Punzi L. Hyperuricemia and tissue monourate deposits: prospective therapeutic considerations. Eur Rev Med Pharmacol Sci. 2015 May;19(9):1549\u20131552.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_3_40_1","volume-title":"Public summary document","author":"Adenuric","unstructured":"Adenuric. Public summary document [Internet]. [cited 2016 Mar 15]. Available from: http:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2015-03\/Files\/febuxostat-psd-march-2015.pdf"},{"issue":"1","key":"e_1_3_3_41_1","first-page":"109","article-title":"Digest of guideline for the management of hyperuricemia and gout: second edition","volume":"34","author":"Japanese Society of Gout and Nucleic Acid Metabolism","year":"2010","unstructured":"Japanese Society of Gout and Nucleic Acid Metabolism. Digest of guideline for the management of hyperuricemia and gout: second edition. Gout and Nucleic Acid Metabolism. 2010;34(1):109\u2013144.","journal-title":"Gout and Nucleic Acid Metabolism"},{"key":"e_1_3_3_42_1","unstructured":"Zyloprim. U.S. Food and Drug Administration. Drugs@FDA. United States. 2015. [cited 2015 Aug 19]. Available from: http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.DrugDetails"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2004.10.031"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M208307200"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90201-R"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645080-00005"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.03016.x"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2013.1414"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1081\/NCN-200027381"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006289848"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250801956350"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03667.x"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1081\/NCN-200027377"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200501000-00005"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005282634"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008322035"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014521389"},{"key":"e_1_3_3_58_1","unstructured":"Febuxostat. ClincalTrials.gov. United States. 2015. [cited 2015 Aug 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/results?term=febuxostat&pg=1"},{"key":"e_1_3_3_59_1","unstructured":"Febuxostat. International Clinical Trials Registry Platform. World Health organization. 2015. [cited 2015 Aug 25]. Available from: http:\/\/apps.who.int\/trialsearch\/default.aspx"},{"issue":"11","key":"e_1_3_3_60_1","first-page":"CD008653","article-title":"Febuxostat for treating chronic gout","volume":"14","author":"Tayar JH","year":"2012","unstructured":"Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME. Febuxostat for treating chronic gout. Cochrane Database Syst Rev. 2012 Nov;14(11):CD008653.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp100394"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20935"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24209"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2978"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken457"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080814"},{"issue":"4","key":"e_1_3_3_68_1","doi-asserted-by":"crossref","first-page":"S35S43","DOI":"10.1097\/RHU.0b013e31821d36cc","article-title":"Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study","volume":"17","author":"Kamatani N","year":"2011","unstructured":"Kamatani N, Fujimori S, Hada T, et al. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study. J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S35S43.","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"e_1_3_3_69_1","doi-asserted-by":"crossref","first-page":"S44S49","DOI":"10.1097\/RHU.0b013e31821d36cc","article-title":"An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study","volume":"17","author":"Kamatani N","year":"2011","unstructured":"Kamatani N, Fujimori S, Hada T, et al. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study. J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S44S49.","journal-title":"J Clin Rheumatol"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31821d36cc"},{"issue":"4","key":"e_1_3_3_71_1","doi-asserted-by":"crossref","first-page":"S19S26","DOI":"10.1097\/RHU.0b013e31821d36cc","article-title":"Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study","volume":"17","author":"Kamatani N","year":"2011","unstructured":"Kamatani N, Fujimori S, Hada T, et al. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S19S26.","journal-title":"J Clin Rheumatol"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-015-3355-5"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005354"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2012.04.011"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000149"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm783"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e318204aab4"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-15-26"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.05.017"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S56597"},{"issue":"5","key":"e_1_3_3_81_1","first-page":"453","article-title":"Cost-effectiveness of febuxostat in chronic gout","volume":"15","author":"Beard SM","year":"2014","unstructured":"Beard SM, von Scheele BG, Nuki G, et al. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2014 Jun;15(5):453\u2013463.","journal-title":"Eur J Health Econ"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0227"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2015.21.2.165"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2016.1149482"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-13-0082"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2014.12.017"},{"key":"e_1_3_3_87_1","unstructured":"Intensive Urate Lowering Therapy With Febuxostat in Comparison With Allopurinol on Cardiovascular Risk in Patients With Gout (FORWARD). ClinicalTrials.gov. United States. 2015. [cited 2015 Aug 27]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02500641"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/17512433.2016.1162094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:18:44Z","timestamp":1772745524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/17512433.2016.1162094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,25]]},"references-count":83,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5,3]]}},"alternative-id":["10.1586\/17512433.2016.1162094"],"URL":"https:\/\/doi.org\/10.1586\/17512433.2016.1162094","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-09-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-03-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}